Cogent Biosciences, Inc.
NASDAQ:COGTBiotechnology
+$0.88 today
- Market cap
- $4.84B
- Beta
- 0.35
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$5.26
Volume 2.71M
Average 2.15M
COGT Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Cogent Biosciences, Inc.NASDAQ: COGT
Operating Income · Q2 FY2026 · quarter ended Jun 2026
Operating income remains negative
Q2 FY2026 operating income was -$102.64M, compared with -$75.58M a year earlier. Trailing-twelve-month operating income was -$389.09M.
Context
- Operating income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 9 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -20.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$102.64M+0.9% QoQ
- Last fiscal yearDec 2025
- -$333.36M-20.8% YoY
- LTMJun 2026
- -$389.09M-29.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -35.8% | +100.0% | +135.8 pp |
| 1 year | -20.8% | +100.0% | +120.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (333.36M) USD
- Year-over-year change
- -20.8%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (333.36M) | -20.8% |
| FY2024 | 2024-12-31 | (275.94M) | -32.6% |
| FY2023 | 2023-12-31 | (208.13M) | -40.8% |
| FY2022 | 2022-12-31 | (147.84M) | -95.7% |
| FY2021 | 2021-12-31 | (75.55M) | — |
Operating Income vs competitors
How COGT compares with its peers on the latest reported figures
- COGT's LTM Jun 2026 operating income of -$389.09M is the 9th highest of the 10 companies compared; the peer median is -$183.47M.
- Its year-over-year change of -29.8% is the 6th highest of 10, against a peer median of -11.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.84B | +89.2% | +31.4% | 31.6% | |
| LTM Aug 2026 | $289.66M | +208.4% | — | 41.3% | |
| LTM Mar 2026 | -$134.05M | -367.0% | — | 670.3% | |
| LTM Mar 2026 | -$156.87M | -11.7% | — | — | |
| LTM Mar 2026 | -$183.47M | +49.1% | — | 81.4% | |
| LTM Mar 2026 | -$223.53M | +35.0% | — | 102.9% | |
| LTM Sep 2026 | -$228.53M | -107.1% | — | — | |
| LTM Mar 2026 | -$317.75M | -56.2% | — | 443.5% | |
| LTM Jun 2026 | -$389.09M | -29.8% | — | — | |
| LTM Jun 2026 | -$486M | -43.8% | — | 415.4% | |
| Peer median (excluding COGT) | -$183.47M | -11.7% | +31.4% | 102.9% | |
Competitors are the stored peer set for COGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 4.62M |
| Gross Profit | 0 | 0 | 0 | 0 | (4.62M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 55.91M | 121.63M | 173.76M | 232.66M | 269.78M |
| Selling, General & Admin | 19.64M | 26.21M | 34.38M | 43.28M | 63.58M |
| Operating Expenses | 75.55M | 147.84M | 208.13M | 275.94M | 328.74M |
| Depreciation & Amortization | 147K | 5.88M | 3.59M | 4.35M | 4.58M |
| EBITDA | (72.13M) | (130.37M) | (188.82M) | (251.51M) | (321.29M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (75.55M) | (147.84M) | (208.13M) | (275.94M) | (333.36M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 467K | 3.99M | 13.08M | 18.09M | 14.69M |
| Interest Expense | 0 | 3.99M | 0 | 0 | 3.06M |
| Other Income / Expenses | 3.28M | 7.6M | 15.72M | 20.08M | 4.43M |
| Income Before Tax | (72.27M) | (140.24M) | (192.41M) | (255.86M) | (328.94M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (72.27M) | (140.24M) | (192.41M) | (255.86M) | (328.94M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.85) | (2.26) | (2.42) | (2.32) | (2.04) |
| EPS (Diluted) | (1.85) | (2.26) | (2.42) | (2.32) | (2.04) |
| Weighted Avg Shares | 38.73M | 58.74M | 79.66M | 110.46M | 160.98M |
| Weighted Avg Shares (Diluted) | 38.73M | 58.74M | 79.66M | 110.46M | 160.98M |
Cogent Biosciences, Inc.
NASDAQ:COGT
Intrinsic Alpha fair value
Locked
Current Price
$27.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.